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Objectives. A large, international, multicenter, prospective,
randomized trial was performed to determine the role of prophy-
lactic intraaortic balloon pump (IABP) counterpulsation after
primary percutaneous transluminal coronary angioplasty (PTCA)
in acute myocardial infarction (AMI).
Background. Previous studies have suggested that routine IABP
use after primary PTCA reduces infarct-related artery reocclusion,
augments myocardial recovery and improves clinical outcomes.
Methods. Cardiac catheterization was performed in 1,100 pa-
tients within 12 h of onset of AMI at 34 clinical centers. Clinical
and angiographic variables were used to stratify patients under-
going primary PTCA into high and low risk groups. High risk
patients were then randomized to 36 to 48 h of IABP (n 5 211) or
traditional care (n 5 226). The study had 80% power to detect a
reduction in the primary end point from 30% to 20%.
Results. There was no significant difference in the predefined
primary combined end point of death, reinfarction, infarct-related
artery reocclusion, stroke or new-onset heart failure or sustained
hypotension in patients treated with an IABP versus those treated
conservatively (28.9% vs. 29.2%, p 5 0.95). The IABP strategy
conferred modest benefits in reduction of recurrent ischemia
(13.3% vs. 19.6%, p 5 0.08) and subsequent unscheduled repeat
catheterization (7.6% vs. 13.3%, p 5 0.05) but did not reduce the
rate of infarct-related artery reocclusion (6.7% vs. 5.5%, p 5 0.64),
reinfarction (6.2% vs. 8.0%, p 5 0.46) or mortality (4.3% vs. 3.1%)
and was associated with a higher incidence of stroke (2.4% vs. 0%,
p 5 0.03). IABP use did not result in enhanced myocardial
recovery as assessed by paired admission to predischarge and
6-week rest and exercise left ventricular ejection fraction.
Conclusions. In contrast to previous studies, a prophylactic
IABP strategy after primary PTCA in hemodynamically stable
high risk patients with AMI does not decrease the rates of
infarct-related artery reocclusion or reinfarction, promote myo-
cardial recovery or improve overall clinical outcome.
(J Am Coll Cardiol 1997;29:1459–67)
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With the publication of randomized trials demonstrating that
primary percutaneous transluminal coronary angioplasty
(PTCA) results in improved patency rates and clinical out-
comes compared with thrombolytic therapy (1–5), PTCA has
been established as a superior method for the early reperfusion
of patients with an acute myocardial infarction (AMI) at
experienced centers. However, patients with adverse high risk
features continue to have excessive morbidity and mortality,
especially in the first 48 h after symptom onset, despite
effective reperfusion therapy (5–14). Previous studies (15–18)
have suggested that the routine use of intraaortic balloon
pump (IABP) counterpulsation after PTCA in AMI may
reduce the rate of infarct-related artery reocclusion, augment
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myocardial recovery and improve clinical outcomes, with an
acceptable safety profile. Such a strategy would be expected to
be most effective in high risk patients with AMI.
We hypothesized that in patients with AMI undergoing
acute cardiac catheterization, readily available clinical and
angiographic variables could prospectively be used to stratify
patients into groups at high and low risk for early morbidity
and mortality and that high risk patients, so identified, might
benefit from a routine IABP strategy after primary PTCA.
Methods
Clinical centers and patients. A total of 34 institutions in
North and South America, Europe and Japan participated in
the Primary Angioplasty in Myocardial Infarction (PAMI)-II
trial. Study sites were diverse and included academic and
community hospitals in urban and rural settings, with a wide
range in annual total PTCA volume for the hospitals (60 to
3,318/year) and individual operators (22 to 507/year).
Patients were enrolled with ongoing chest pain up to 12 h in
duration, with electrocardiographic (ECG) evidence of AMI
(ST segment elevation $1 mm in two contiguous leads).
Patients with ST segment depression, left bundle branch block
or other nondiagnostic ECG patterns were included if acute
catheterization demonstrated an occluded vessel with regional
left ventricular dysfunction. Exclusion criteria included cardio-
genic shock; bleeding diathesis prohibiting the use of aspirin or
heparin; and precatheterization administration of thrombolytic
therapy. Written informed consent was obtained from all
patients.
Catheterization and PTCA procedure. Patients who met
enrollment criteria were treated in the emergency room with
324 mg of chewable soluble aspirin, a 5,000- to 10,000-U bolus
of intravenous heparin, intravenous nitroglycerin and, in the
absence of contraindications, intravenous followed by oral
beta-blockade. Patients were taken emergently to the cardiac
catheterization laboratory, where left ventriculography and
coronary arteriography were performed. Ionic contrast agents
were used to minimize the risk of thromboembolic complica-
tions (19,20). After angiography, PTCA was deferred if spon-
taneous reperfusion was found with an infarct stenosis ,70%
or if a small vessel was occluded that would best be treated
conservatively. Primary coronary artery bypass graft surgery
was recommended rather than PTCA for patients with unpro-
tected left main stenosis .60%, severe triple-vessel disease
with a patent infarct-related vessel or features unfavorable for
PTCA. Before PTCA, additional heparin was given to main-
tain the activated clotting time (Hemochron) .350 s. PTCA
was performed in the infarct-related vessel only, with the goal
of obtaining a ,50% residual stenosis and restoring brisk
anterograde flow. Stenting (1.3%) and atherectomy (1.2%)
were rarely used during the time period of this study.
Acute risk stratification and randomization. After cathe-
terization, patients were stratified into high and low risk groups
on the basis of clinical and angiographic variables. Patients
were considered to be high risk if one or more of the following
criteria were met: age .70 years, three-vessel disease, left
ventricular ejection fraction (LVEF) #45%, vein graft occlu-
sion, persistent malignant ventricular arrhythmias or a subop-
timal PTCA result. If none of these criteria were present, the
patient was stratified as low risk.
Patients stratified as high risk were considered eligible for
randomization unless an IABP was contraindicated because of
peripheral vascular disease, aortic aneurysm or aortic valve
insufficiency or if an IABP was required because of clinical or
hemodynamic instability. At the completion of the PTCA
procedure, high risk eligible patients were randomized to
either placement of an IABP for 36 to 48 h (inserted percuta-
neously using the same femoral entry site that had been used
for PTCA) or conservative, traditional care. Low risk patients
were randomized into accelerated discharge and traditional
care groups. As previously reported (21), in-hospital and
postdischarge outcomes were similar in both arms of the low
risk study. High risk patients not eligible for randomization
were treated clinically as appropriate and followed up in a
registry.
Hospital course. After catheterization, high risk patients
were admitted to the coronary care unit. Intravenous heparin
was maintained $72 h to keep the prothrombin time 1.5 to 2.0
times control levels, then tapered over 12 h to avoid a rebound
hypercoagulable state (22). The heparin infusion was inter-
rupted when appropriate to remove the femoral sheaths or
IABP, or both, after which the drip was reinstituted. Per
protocol, patients were treated with soluble aspirin (325 mg
orally every day), intravenous nitroglycerin for 24 h and beta-
blockade in the absence of contraindications. Angiotensin-
converting enzyme inhibition was recommended for left ven-
tricular dysfunction or hypertension.
In the absence of contraindications, predischarge catheter-
ization was performed in high risk patients for assessment of
infarct-related artery patency and left ventricular function.
Patients were discharged when clinically stable. Six weeks after
discharge, rest and exercise radionuclide ventriculography was
recommended to further assess myocardial recovery.
Definitions. Successful PTCA was defined as a ,50% re-
sidual stenosis with Thrombolysis in Myocardial Infarction
(TIMI) grade 2 or 3 flow. Reinfarction was defined as recurrent
clinical symptoms in association with any increase in creatine
kinase, MB fraction (CK-MB) above its previous nadir. Recur-
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
CABG 5 coronary artery bypass graft surgery
CK-MB 5 creatine kinase, MB fraction
ECG 5 electrocardiographic
IABP 5 intraaortic balloon pump
LVEF 5 left ventricular ejection fraction
PAMI 5 Primary Angioplasty in Myocardial Infarction
PTCA 5 percutaneous transluminal coronary angioplasty
TIMI 5 Thrombolysis in Myocardial Infarction
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rent ischemia was defined as clinical symptoms associated with
either new ECG ST segment or T wave changes, hypotension,
new murmur, CK-MB elevation or necessity for urgent repeat
PTCA or coronary artery bypass graft surgery (CABG). Con-
gestive heart failure was defined as Killip class 2 to 4 heart
failure. Sustained hypotension was defined as systolic blood
pressure ,90 mm Hg for .30 min or requiring intravenous
vasopressors.
Data collection and statistical analysis. Clinical data were
collected prospectively at each site by a research nurse. For
quality control, an independent study monitor traveled to each
site to cross reference case report forms and medical records.
After confirmation, data were entered into a computerized
data base. Independent core laboratory angiographic analysis
was performed by a technician in blinded manner with regard
to the randomization scheme. Residual stenosis was determined
by electronic calipers and TIMI flow grades by visual assess-
ment (23). Global LVEF was calculated by the area–length
method (24), and regional wall motion was determined by the
centerline chord method (25).
The primary end point in high risk patients was prespecified
as the combined incidence of in-hospital death, reinfarction,
infarct-related artery reocclusion, stroke or postadmission new
onset congestive heart failure or sustained hypotension. The
study was powered such that for 310 high risk patients enrolled
and randomized, it would be able to detect a two-tailed
reduction in the primary end point from 35% to 20% with 80%
likelihood at a significance level of p 5 0.05, considered a
clinically relevant reduction. Unless otherwise stated, analysis
was made on an intention to treat basis. Categoric variables
were compared by chi-square analysis or Fisher exact test.
Continuous variables are presented as mean value 6 SD and
were compared by Student t test or Mann-Whitney U test. All
p values are two-tailed. An independent Data and Safety
Monitoring Board reviewed the interim results after 400 and
800 patients were enrolled and recommended that the study
continue.
Results
Patient enrollment and baseline features. Between Sep-
tember 1993 and January 1995, acute angiography was per-
formed in 1,100 patients with an AMI at 34 clinical centers, 982
of whom (89%) underwent primary PTCA. After clinical,
hemodynamic and angiographic assessment, 908 patients were
considered eligible for randomization, whereas 192 patients
were followed up in the registry. After PTCA, randomizable
patients were risk stratified into high risk (n 5 437) and low
risk groups (n 5 471). As seen in Table 1, among randomizable
patients, the risk-stratification process identified a cohort of
patients with significantly increased rates of in-hospital death,
reinfarction, recurrent ischemia, new onset of heart failure or
sustained hypotension, need for CABG and prolonged hospital
stay.
High risk patients were subsequently randomized to receive
an IABP for 36 to 48 h (n 5 211) versus conservative care (no
IABP, n 5 226). There were no significant differences in the
rates of high risk qualifying features, baseline demographic
and angiographic characteristics or outcome of primary PTCA
between high risk patients randomized to IABP versus conser-
vative care (Table 2).
Randomization and protocol compliance. After PTCA,
IABP counterpulsation was established in 182 (86.3%) of 211
patients randomized to an IABP. In 29 patients, an IABP was
not placed because of peripheral vascular disease (n 5 8),
IABP malfunction (n 5 8), IABP unavailability (n 5 3),
patient refusal (n 5 3), physician preference (n 5 3) or other
(n 5 4). In patients in whom the device was placed, the mean
(6SD) duration of IABP counterpulsation was 47.9 6 28.0 h.
In 26 (11.5%) of 226 patients assigned to conservative treat-
ment, an IABP was required for hemodynamic instability (n 5
18), persistent ischemia (n 5 7), abrupt vessel reocclusion (n 5
3) or severe dissection or thrombosis (n 5 3).
Predischarge repeat catheterization was completed in 330
(85%) of 389 eligible patients, including 165 randomized to an
IABP and 165 assigned to conservative treatment. Forty-eight
patients were ineligible for the predischarge study because of
death (n 5 16), CABG (n 5 21) or major illness or contrain-
dications to repeat angiography, including renal impairment,
stroke or confusion (n 5 11).
In-hospital outcome. As seen in Figure 1, when the 437
randomized high risk patients in an intention to treat analysis
were considered, there were no significant differences in major
clinical adverse events or occurrence of the predefined primary
end point in patients assigned to a prophylactic IABP strategy
versus traditional care, except for a slightly higher incidence of
stroke in patients assigned to IABP. The findings were similar
when only the 382 randomized patients who actually received
the assigned treatment were considered. Secondary clinical
end points are shown in Table 3, and also did not vary between
the two groups, except for a somewhat lower incidence of
persistent chest pain and recurrent ischemia in patients ran-
domized to IABP, with an associated reduction in the necessity
for unscheduled predischarge catheterization.
Vascular and bleeding complications (Table 4). Hemor-
rhagic complications were more frequent in patients assigned
to routine IABP usage, primarily because of an increased
Table 1. In-Hospital Outcomes of 908 Randomized Patients Risk
Stratified Into High Risk and Low Risk Groups
High Risk Group
(n 5 437)
Low Risk Group
(n 5 471)
p
Value
Death (%) 3.7 0.4 0.0002
Reinfarction (%) 7.1 2.8 0.001
Recurrent ischemia (%) 16.5 7.6 , 0.0001
Stroke (%) 1.1 0.9 0.75
Postadmission new-onset HF
or hypotension (%)
21.5 5.3 , 0.0001
CABG (%) 11.2 1.9 , 0.0001
Length of hospital stay (days) 10.3 6 7.9 5.6 6 4.0 , 0.0001
Data presented are mean value 6 SD or percent of patients. CABG 5
coronary artery bypass graft surgery; HF 5 heart failure.
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incidence of access site bleeding. However, there was no
difference in the rate of blood transfusion or fall in hematocrit
during the hospital period. Similarly, major vascular complica-
tions occurred rarely and were not increased by the IABP
strategy.
Myocardial salvage. Paired acute and predischarge left
ventriculography was available for 217 patients. In patients
randomized to IABP, LVEF rose from 47.2% 6 9.7% during
the acute infarction study to 49.8% 6 9.1% during predis-
charge catheterization (p 5 0.002). In patients treated conser-
vatively, LVEF rose from 48.5% 6 11.2% to 50.7% 6 9.8%,
respectively (p 5 0.02). As shown in Figure 2, there were no
significant differences in the improvement in global LVEF and
infarct zone regional wall motion between patients randomized
to IABP versus conservative care.
Radionuclide ventriculography was performed 6 weeks
after hospital discharge in 183 patients. No significant
treatment-related differences were present in either rest or
exercise LVEF (Figure 3).
Outcomes of high risk randomized versus registry patients.
Among the 192 nonrandomized patients followed up in the
registry, 144 (75%) would have met criteria for high risk. The
reasons for no randomization of these patients are shown in
Table 5. Compared with high risk randomized patients, high
risk registry patients had a lower mean acute LVEF (44% 6
15% vs. 50% 6 12%, p , 0.0001), were more likely to have
triple-vessel disease (51.4% vs. 29.8%) and to require in-
hospital CABG (43.1% vs. 11.2%, p , 0.0001); they also had a
higher in-hospital mortality rate (9.0% vs. 3.7%, p 5 0.02).
PTCA was performed in 66 high risk registry patients (45%), 9
of whom (13.6%) died. An IABP was clinically required in 58
high risk registry patients (40%) (in the catheterization labo-
ratory in 33 patients and later in the hospital course in 25
patients). As seen in Table 6, in-hospital outcomes in high risk
registry patients who clinically required an IABP were signif-
icantly worse than in those who were able to be managed
conservatively.
Discussion
IABP counterpulsation after primary PTCA—results of
previous studies. Reocclusion of the infarct-related artery has
been documented in 8% to 20% of patients after successful
primary PTCA for AMI and results in blunted myocardial
recovery (26–29). Approximately 50% of infarct-related artery
reocclusions result in clinical reinfarction (29,30), which is the
second most common cause of death after successful reperfu-
sion (31). Adjunctive pharmacologic and mechanical strategies
have therefore been sought to prevent infarct-related artery
reocclusion after successful reperfusion.
Experimental and clinical studies with IABP counterpulsa-
tion in patients with AMI and after PTCA have demonstrated
augmented proximal coronary blood flow velocity (32–34),
suggesting that infarct-related artery reocclusion may be re-
duced by IABP use after mechanical reperfusion in AMI.
Furthermore, the beneficial hemodynamic effects of IABP
counterpulsation in reducing preload and afterload may also
promote ventricular recovery after AMI (35). Ishihara et al.
(15) studied the outcomes of 114 patients with AMI undergo-
ing PTCA with or without antecedent thrombolytic therapy in
two consecutive time periods. Compared with 66 patients
Table 2. Baseline Demographic and Angiographic Characteristics
and Coronary Angioplasty Outcomes in 437 High Risk Patients
Randomized to Intraaortic Balloon Counterpulsation Versus
Conservative Care
IABP
(n 5 211)
No IABP
(n 5 226)
p
Value
Demographic features
Age (yr) 64.7 6 11.9 63.7 6 13.0 0.69
Female gender (%) 25.1 24.8 0.93
Hypertension (%) 54.8 55.7 0.86
Hypercholesterolemia (%) 37.2 35.9 0.78
Diabetes mellitus (%) 21.3 14.6 0.07
Current cigarette smoking (%) 33.5 30.8 0.55
Prior peripheral vascular disease (%) 5.0 3.2 0.34
Prior MI (%) 21.4 21.7 0.94
Prior CABG (%) 7.5 5.9 0.52
Prior CHF (%) 3.5 3.2 0.86
Admission Killip class $2 (%) 21.7 22.2 0.95
Admission HR (beats/min) 79 6 17 81 6 36 0.51
Admission SBP (mm Hg) 130 6 26 129 6 25 0.52
Time from symptom onset to
hospital arrival (min)
149 6 139 146 6 140 0.83
Time from symptom onset to
angiography (min)
262 6 167 257 6 154 0.54
Angiographic features (%)
1 VD (%) 43.6 51.8
2 VD (%) 24.2 20.8 0.23
3 VD (%) 32.2 27.4
Acute LVEF (%) 49.4 6 12.5 50.1 6 11.3 0.58
IRA
LAD (%) 52.3 49.8
LCx (%) 11.3 10.1 0.67
RCA (%) 36.4 40.1
Initial infarct lesion stenosis (%) 96 6 8 97 6 7 0.47
Initial TIMI flow grade 0–1 80.6 81.1 0.89
High risk qualifying features
Age .70 yr 35.6 39.4 0.41
LVEF #45% 58.6 51.8 0.16
3 VD 32.2 27.4 0.29
Saphenous vein graft angioplasty 4.3 3.6 0.70
Refractory ventricular arrhythmias 7.1 6.8 0.86
Suboptimal angioplasty result 13.3 14.2 0.77
Outcome of primary PTCA
Post-PTCA infarct lesion
stenosis (%)
29 6 14 29 6 14 0.93
PTCA successful (%) 97.3 96.2 0.55
TIMI grade 3 flow restored (%) 92.6 91.2 0.78
Data presented are mean value 6 SD or percent of patients. CABG 5
coronary artery bypass graft surgery; CHF 5 congestive heart failure; HR 5
heart rate; IABP 5 intraaortic balloon pump counterpulsation; IRA 5
infarct-related artery; LAD 5 left anterior descending coronary artery;
LCx 5 left circumflex coronary artery; LVEF 5 left ventricular ejection
fraction; PTCA 5 percutaneous transluminal coronary angioplasty; RCA 5
right coronary artery; SBP 5 systolic blood pressure; TIMI 5 Thrombolysis
in Myocardial Infarction; VD 5 vessel disease.
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treated with conventional therapy, patients who received an
IABP for 25 6 8 h after reperfusion had a lower rate of
infarct-related artery reocclusion (2% vs. 18%, p 5 0.03) and
reinfarction (0% vs. 7%, p 5 0.04) and greater improvement in
serial LVEF (9.2 6 13.0% vs. 4.5 6 12.2%, p 5 0.08).
Ohman et al. (16), in a retrospective analysis of four
thrombolytic trials, found that the rate of infarct-related artery
reocclusion was reduced, and recovery of noninfarct zone
regional wall motion was enhanced in patients nonrandomly
treated with IABP counterpulsation for clinical deterioration.
On the basis of these observations, a randomized, multicenter
trial was performed in which 182 patients within 24 h onset of
AMI who achieved successful reperfusion by either primary
PTCA, rescue PTCA after failed thrombolysis on intracoro-
nary thrombolysis or who had documented triple-vessel disease
with a patent infarct-related vessel were randomized to 48 h of
IABP counterpulsation or traditional care (17). Patients ran-
domized to IABP had a lower rate of infarct-related artery
reocclusion (8% vs. 21%, p , 0.03), recurrent ischemia (4% vs.
21%, p 5 0.001) and emergency PTCA (2% vs. 11%, p , 0.02).
The reduction in infarct-related artery reocclusion afforded by
IABP counterpulsation was particularly pronounced in the
subgroup of patients undergoing primary PTCA without ante-
cedent thrombolysis (4% vs. 18%).
Figure 1. In-hospital major adverse outcomes in 437
high risk patients with AMI randomized to prophylactic
IABP counterpulsation versus conservative care after
reperfusion by primary PTCA. IRA 5 infarct-related
artery. Heart failure/hypotension 5 new onset of post-
admission congestive heart failure or sustained hypoten-
sion.
Table 3. Secondary In-Hospital Outcomes in 437 Randomized High
Risk Patients
IABP
(n 5 211)
No IABP
(n 5 226)
p
Value
Persistent/recurrent chest pain and
ischemic end points
Persistent postangioplasty chest
pain (%)
3.3 7.5 0.05
Recurrent chest pain w/o ECG
changes (%)
10.4 15.0 0.15
True recurrent ischemia (%) 13.3 19.6 0.08
Nonprotocol predischarge cath (%) 7.6 13.3 0.05
Nonprotocol predischarge IRA
PTCA (%)
4.7 4.0 0.70
Hemodynamic end points
CHF (%) 17.5 19.5 0.60
Pulmonary edema (%) 6.6 9.3 0.31
Transient hypotension (%) 4.7 8.9 0.09
Sustained hypotension (%) 7.1 8.9 0.50
Vasopressor use (%) 22.0 25.1 0.54
Cerebrovascular end points
Hemorrhagic stroke (%) 1.0 0 0.23
Nonhemorrhagic stroke (%) 1.4 0 0.11
TIA (%) 0.5 0 0.48
Arrhythmic end points
VT (%) 5.2 5.3 0.96
VF (%) 1.4 2.7 0.51
Symptomatic bradyarrhythmias (%) 5.7 4.4 0.55
Other end points
Intubation (%) 8.1 5.3 0.25
Dialysis (%) 1.9 0.4 0.20
CABG (%) 11.9 10.7 0.70
Hospital days 10.5 6 7.4 10.0 6 8.3 0.50
Data presented are mean value or percent of patients. cath 5 catheteriza-
tion; ECG 5 electrocardiographic; TIA 5 transient ischemic attack; VF 5
ventricular fibrillation; VT 5 ventricular tachycardia; other abbreviations as in
Table 2.
Table 4. Vascular and Hemorrhagic Complications in the
Study Cohort
IABP
(n 5 211)
no IABP
(n 5 226)
p
Value
Any hemorrhagic complication (%) 36.0 27.4 0.05
Access site hemorrhage (%) 20.9 13.3 0.03
Retroperitoneal hemorrhage (%) 1.0 0.9 1.0
Gastrointestinal hemorrhage (%) 6.6 5.3 0.56
Genitourinary tract hemorrhage (%) 3.8 6.6 0.18
Cerebrovascular hemorrhage (%) 1.0 0 0.23
Postoperative hemorrhage (%) 7.6 4.9 0.24
Undetermined source (%) 6.2 7.6 0.56
Other (%) 2.4 3.5 0.64
Fall in hct (from admission to nadir) (%) 10.7 6 6.4 10.2 6 7.1 0.30
Any blood transfusion (%) 19.9 17.7 0.56
From access site or retroperitoneal
bleed (%)
4.7 2.6 0.18
Loss of peripheral pulse (%) 0 0.9 0.50
Pseudoaneurysm or arteriovenous
fistula (%)
1.4 1.3 1.0
Deep venous thrombosis (%) 0 1.3 0.25
Sepsis (%) 0.9 0.9 1.0
Vascular surgical repair (%) 0.5 0.4 1.0
Data presented are mean value 6 SD or percent of patients. hct 5
hematocrit; IABP 5 intraaortic balloon pump counterpulsation.
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The present study. In this trial, clinical and angiographic
variables readily obtainable at the time of acute cardiac
catheterization were able to prospectively identify patients
with an AMI at markedly increased risk for in-hospital mor-
tality, reinfarction, recurrent ischemia, heart failure and hypo-
tension despite effective reperfusion. As previously reported
(36), even after all clinical determinants by multivariate anal-
ysis were accounted for, the catheterization-derived variables
of reduced LVEF, three-vessel disease or failed reperfusion
predicted patients with a 3.8-fold increased mortality. The
ability to prognostically stratify patients after primary PTCA
while still in the cardiac catheterization laboratory is poten-
tially a major advantage of the invasive approach; high risk
patients so identified may benefit from adjunctive pharmaco-
logic or mechanical strategies, whereas low risk patients may
be safely treated with accelerated discharge (21).
Unfortunately, in contrast to the favorable effects of IABP
counterpulsation found in the earlier trials, in the present
larger study, the routine use of an IABP for 36 to 48 h after
primary PTCA in high risk but hemodynamically stable pa-
tients had no significant beneficial effects on preventing
infarct-related artery reocclusion or reinfarction or on promot-
ing myocardial recovery either in the infarct zone or noninfarct
zone. Modest benefits were seen with the IABP in reducing
recurrent ischemia and the subsequent need for urgent repeat
catheterization. However, with appropriate management of
these events, survival free of reinfarction and late ventricular
function were similar in both groups. Furthermore, a statisti-
cally significant increase in stroke was present in patients
treated with an IABP. This finding may have been due to
chance: One stroke was embolic after new-onset atrial fibril-
lation; one occurred after prolonged hypotension and intuba-
tion; one occurred postoperatively; and one, in retrospect, was
present on admission; one intracranial hemorrhage developed
after a postinfarction patient was hit in the head with a shovel
while robbing the hospital nursery. Nonetheless, the possibility
that the presence of the large-caliber pulsatile IABP in the
vasculature for 48 h contributed to the increased stroke rate
cannot totally be disregarded.
The lack of benefit of the IABP strategy in the present trial
cannot be attributed to poor outcomes in the IABP arm. Given
the high percentage of elderly patients with left ventricular
dysfunction comprising the high risk population, the rates of
mortality (4.3%), reinfarction (6.2%) and infarct-related artery
reocclusion (6.7%) are favorable. Furthermore, the routine
use of the IABP for 48 h did not result in an excessive rate of
major complications attributable to the device. In contrast to
the high incidence of adverse events when IABP counterpul-
Figure 3. Rest and exercise LVEF measured by radionuclide ventricu-
lography 6 weeks after hospital discharge. Format as in Figure 2.
Table 5. Reasons for Excluding 144 High Risk Patients
From Randomization
Primary PTCA not performed after acute angiography 79 (55%)
CABG planned for LMCA or 3 VD or anatomy unsuitable
for PTCA
50
Spontaneous reperfusion with ,70% IRA stenosis 19
Large thrombus treated only with intracoronary thrombolysis 5
IRA supplied a small amount of myocardium, left occluded 3
Other 2
IABP required for development of hypotension, shock, acute
occlusion or severe dissection after PTCA
33 (23%)
Physician preference 10 (7%)
Peripheral vascular disease or abdominal aortic aneurysm
identified contraindicating IABP
8 (6%)
IABP required after failed PTCA before CABG 5 (3%)
Not sure of culprit lesion 2 (1%)
Other 7 (5%)
Data presented are number (%) of patients. LMCA 5 left main coronary
artery; other abbreviations as in Table 2.
Table 6. Selected Outcomes in High Risk Registry Patients
Stratified by Requirement for Intraaortic Balloon Counterpulsation
IABP
Required
(n 5 58)
IABP
Not
Required
(n 5 86)
p
Value
Death (%) 15.5 4.7 0.03
Reinfarction (%) 5.2 2.3 0.39
Recurrent ischemia (%) 19.0 7.8 0.03
Hypotension or CHF (%) 70.7 3.5 , 0.0001
CABG (%) 51.7 37.2 0.08
Hospital days 11.4 6 7.6 7.5 6 3.8 , 0.0001
Data presented are mean value 6 SD or percent of patients. Abbreviations
as in Table 2.
Figure 2. Change in global LVEF, infarct zone regional wall motion
and non–infarct zone regional wall motion in patients with paired left
ventriculographic studies from admission to predischarge. Results
presented are group mean values with standard error bars. A positive
value represents improvement in variable from admission to discharge.
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sation is required for patients in shock and multisystem failure
(37–39), major hemorrhagic, vascular and infectious events in
the present study were rare and not increased by the IABP.
The lack of benefit of routine IABP use in PAMI-II
compared with previous studies also cannot be attributed to a
lower risk cohort being enrolled in the present study. Com-
pared with the previous reports (15,17), patients in the present
study were older, more likely to have triple-vessel disease and
had similar left ventricular function. Indeed, the risk-
stratification process identified a high risk cohort for random-
ization with a ninefold increased mortality rate compared with
that for the nonenrolled low risk patients. Although patients
who developed shock, refractory heart failure or severe, per-
sistent ischemia were not randomized for ethical reasons, only
38 (3.5%) of 1,100 patients were excluded on this basis, which
also was an exclusion criteria in the randomized trial by
Ohman et al. (17).
The more likely explanation for the relative lack of benefit
of prophylactic IABP use in the present trial is that the control
group had a better than expected outcome. The in-hospital
mortality rate of only 3.1% in the conservatively treated high
risk patients in this trial is particularly noteworthy given that
they were 4 to 8 years older than those in previous studies
(15,17). Furthermore, the documented infarct-related artery
reocclusion rate of 5.5% in the conservative arm of the present
study is significantly lower than the 17.7% and 20.8% rates of
reocclusion found in the control patients of the previous
studies (15,17). Although the use of thrombolytic therapy
before PTCA in a significant proportion of patients in the
earlier IABP trials may have increased the rate of reocclusion
in the control patients compared with use of a primary PTCA
strategy (40,41), 18% of patients undergoing primary PTCA in
the multicenter randomized trial also experienced reocclusion.
Although speculative, other factors, such as the use of ionic
contrast agents (19,20), meticulous attention to anticoagula-
tion status (including precatheterization chewable aspirin and
requiring an activated clotting time .350 s at the time of
PTCA [42]), avoidance of undersized balloons to obtain the
largest minimal lumen diameter possible (43–45) and perse-
verance until TIMI grade 3 flow was restored (achieved in 92%
of patients), may underlie the improved outcome of the
patients undergoing primary PTCA without IABP counterpul-
sation in the present study. Regardless, the equivalent rates of
restoration of TIMI grade 3 flow, reinfarction and infarct-
related artery reocclusion among patients treated with or
without an IABP resulted in similar survival, with a commen-
surate degree of myocardial recovery in both groups (5,46).
Study limitations. Several potential limitations of this
study should be acknowledged: 1) With 437 high risk patients
randomized, the study had 80% power to detect a reduction in
the primary end point from 30% to 20%. Although lesser
degrees of benefit cannot be excluded, the nearly identical 29%
occurrence of the primary end point in both arms suggests that
major benefits or hazards of routine IABP use are unlikely to
exist. 2) Because the lack of major benefit of the IABP strategy
in this trial may be explained by the excellent outcomes in the
control arm, the results of the present study may not apply to
hospitals or operators that cannot recreate these results.
However, among the large number of centers and physicians
with varying skill levels who participated in PAMI-II, no major
differences in outcomes were found on the basis of PTCA
experience or hospital setting (47), suggesting that the results
of the present study are generalizable to many institutions. 3)
It remains possible, albeit presently unproved, that prophylac-
tic IABP counterpulsation may be useful in selected settings,
such as in patients with heart failure or hypotension or
post-PTCA dissection. The present study also does not exclude
a potential role for the IABP after rescue PTCA for failed
thrombolysis, wherein reocclusion rates are known to be
increased (40). There may also be a role for prophylactic IABP
placement before rather than after mechanical reperfusion in
selected high risk patients to prevent hemodynamic deteriora-
tion (48).
The establishment of IABP counterpulsation has proven
utility and is mandatory before catheterization in patients with
AMI and cardiogenic shock and is clinically useful in the broad
range of high risk patients represented in the PAMI-II registry,
including patients with resistant heart failure, mechanical
complications of AMI, refractory infarct-related vessel reoc-
clusion and as a bridge to operation (49). However, the 40% to
50% mortality rate of patients with shock despite PTCA and
IABP counterpulsation and the adverse outcomes of shock
patients without shock requiring an IABP (Table 6), empha-
size the continuing need for more effective approaches for the
most critically ill patients.
Appendix
Participating Institutions and Investigators for the
Second Primary Angioplasty in Myocardial Infarc-
tion (PAMI-II) Study
Coordinating center: William Beaumont Hospital, Royal Oak, Michigan:
Cindy L. Grines, MD, Principal Investigator, Lorelei Grines, PhD, Debra Sachs,
MS, Denise Jones, RN, BSN, Mariann Graham, RN, BSN, Phyllis McKinney,
Holly Jewett, Antoinette Kreis.
Clinical Centers: William Beaumont Hospital, Royal Oak, Michigan: Cindy L.
Grines, MD, William W. O’Neill, MD, Dominic Marsalese, MD, Marc Brodsky,
MD, H. Friedman, MD, V. Gangadharan, MD, L. Goldman, MD, R. Levin, MD,
G. Pavlides, MD, R. Ramos, MD, R. Safian, MD, V. Savas, MD, T. Schreiber,
MD, S. Ajluni, MD, S. Almany, MD, J. Boatman, MD, Denise Jones, RN, BSN,
Denise Mason, RN, BSN; El Camino Hospital, Mountain View, CA: Gregg W.
Stone, MD, Fred G. St. Goar, MD, C. Bavor, MD, R. Constantino, MD, M.
Klughaupt, MD, I. Saah, MD, E. Bough, MD; Stanford University Hospital,
Stanford, California: Stephen Osterle, MD, Gregg W. Stone, MD, Cheryl
McWard, RN; Moses H. Cone Hospital, Greensboro, North Carolina: Bruce R.
Brodie, MD, Thomas D. Stuckey, MD, Richard A. Weintraub, MD, Tracie
Gregory, RN; Virginia Beach General Hospital, Virginia Beach, Virginia: John J.
Griffin, MD, Denise R. Bondy, BA, RN; Allegheny General Hospital, Pittsburgh,
Pennsylvania: Bryan Donohue, MD, David M. Lasorda, DO, Richard Begg, MD,
Susan Petruolo, RN; Hospital Santa Case de Misericordia, Curitiba, Brazil:
Costantino Costantini, MD, Eny Goeder, RN; Instituto Modelo de Cardiologia,
Cordoba, Argentina: Carlos Balestrini, MD, Cesar Serra, MD, Jose Sala, MD;
Exeter and Portsmouth Regional Hospitals, Exeter and Portsmouth, New Hamp-
shire: Thomas P. Wharton, Jr., MD, James M. Schmitz, MD, Frank A. Fedele,
MD, Nancy McNamara, RN; St. Joseph’s Hospital and Health Center, Syracuse,
New York: Paolo Esente, MD, Susan Wagner, RN; St. Francis Hospital, Tulsa,
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Oklahoma: Michael G. Spain, MD, Victoria Wagner, RN; Lenox Hill Hospital,
New York, New York: Jeffrey Moses, MD, Nancy Cohen, RN; Kokura Memorial
Hospital, Kitakyushu, Japan: Masakiyo Nobuyoshi, MD, Yoshihisa Nakagawa,
MD; Fort Sanders Regional Medical Center, Knoxville, Tennessee: Mike Ayers,
MD, Dan Slutzker, MD, Jane Souther, MD, Vicki Rhule, RN; Mid America
Heart Institute, Kansas City, Missouri: Thomas Shimshak, MD, Geoffrey O.
Hartzler, MD, Patty Eikenberry, LPN, Cheryl Dreiling, RN; St. Vincent Hospital,
Indianapolis, Indiana: Don Rothbaum, MD, Tom Linnemeier, MD, Susan
Gowen, RN; United Hospital, Grand Forks, North Dakota: Noah Chelliah, MD,
Carolyn Gray, RN; Hospital General “Gregorio Maranon,” Madrid, Spain: Juan
Luis Delcan, MD, Jore Lopez Sandor, MD, Eulogio Garcia, MD; Lakeland
Regional Medical Center, Lakeland, Florida: Kevin F. Browne, MD, Ronald
Vlietstra, MD, Mary Telatnik, RN; Methodist Hospital, Lubbock, Texas: Paul
Overlie, MD, Karen Davis, RN; St. Patrick Hospital, Missoula, Montana: W. Stan
Wilson, MD, Katie MacKey, RN; St. Joseph Medical Center/Elkhart General
Hospital, South Bend, Indiana: Donald Westhausen, Jr., MD, Dawn Edwards,
MS, RN; Guthrie Healthcare System, Sayre, Pennsylvania: Marcus Sodums, MD,
Victoria Schiefen, RN, Kamie Hoey, RN; Providence Hospital, Portland, Oregon:
Bradley Evans, MD, Karen Rydell, RN; Florida Hospital South, Orlando, Florida:
Russell Ivanhoe, MD, A. Ralph Rodriguez, MD, Mary Reynolds, RN; The Heart
Institute of St. Joseph Hospital, Atlanta, Georgia: Christopher Cates, MD, William
Knopf, MD, Jan Sheftel, RN; Eastern Carolina University School of Medicine,
Greenville, North Carolina: A. Kahn, MD; Riverside Hospital, Columbus, Ohio:
Nathan Kander, MD; North Shore University Hospital, Manhasset, New York:
Stanley Katz, MD, Lisa Chepurko, RN; Wake Medical Center, Raleigh, North
Carolina: Joel Schneider, MD; State University of New York at Stony Brook, Stony
Brook, New York: John P. Dervan, MD; St. John Hospital, Detroit, Michigan:
Theodore Schreiber, MD, Christine Trevino, RN; Baptist Memorial Hospital,
Memphis, Tennessee: Joseph Samaha, MD, Barbara Hamilton, RN; The Heart
Center of Fort Wayne, Fort Wayne, Indiana: Brian Lew, MD; Hinsdale Hospital,
Hinsdale, Illinois: Jerome Hines, MD.
Data and Safety Monitoring Board: William Beaumont Hospital, Royal Oak,
Michigan: Gerald Timmis, MD; University of Michigan Medical Center, Ann Arbor,
Michigan: Bertram Pitt, MD; Boston University, Boston, Massachusetts: Thomas J.
Ryan, MD.
Core Angiographic Laboratory: William Beaumont Hospital, Royal Oak,
Michigan: Sandeep Khurana, MD, Mariann Graham, RN, BSN, Ludmilla Mitina.
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